

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID: SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 27 SEP 18 Support for STN Express, Versions 6.01 and earlier, to be discontinued

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:15:55 ON 19 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:16:06 ON 19 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 SEP 2008 HIGHEST RN 1049989-16-3
DICTIONARY FILE UPDATES: 17 SEP 2008 HIGHEST RN 1049989-16-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10581340\1.str



chain nodes :
 1 2 3 4 5 6 7 8 14 18
 ring nodes :
 9 10 11 12 13
 chain bonds :
 1-2 2-3 2-5 3-4 3-6 7-8 13-14
 ring bonds :
 9-10 9-13 10-11 11-12 12-13
 exact/norm bonds :
 2-5 3-4 3-6 7-8 9-10 9-13 10-11 11-12 12-13 13-14
 exact bonds :
 1-2 2-3

G1:NO2, [*1], [*2]

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom
 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 18:CLASS



L1 STRUCTURE UPLOADED

=> D

L1 HAS NO ANSWERS

L1 STR

G1



G1 NO2, [@1], [@2]

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 14:16:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5619 TO ITERATE35.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


31 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 107885 TO 116875
PROJECTED ANSWERS: 1182 TO 2300

L2 31 SEA SSS SAM L1

=> D SCAN

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinepropanoic acid, 2-methyl-5-nitro- α -oxo-, ethyl ester
 MF C11 H12 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Glycinamide, N-[(5-(4-chlorophenyl)-2-furanyl)carbonyl]-L-isoleucyl-3-cyclohexyl-L-alanyl-(3S)-3-amino-2-oxopentanoyl-N-[(3-nitrophenyl)sulfonyl]- (9CI)
 SQL 4
 MF C39 H47 Cl N O11 S


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L- α -aspartyl-N-[(4-[(imino(nitroamino)methyl)amino]-1-[oxo[(3-phenylpropyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI)
 MF C37 H50 N8 O10


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Pyruvic acid, [4-(benzylthio)-2-nitrophenyl]- (7CI)
 MF C16 H13 N O5 S







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\STNEXP\Queries\10581340\2.str



```

chain nodes :
1 2 3 4 5 6 12
ring nodes :
7 8 9 10 11
chain bonds :
1-2 2-3 2-5 3-4 3-6 11-12
ring bonds :
7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
2-5 3-4 3-6 7-8 7-11 8-9 9-10 10-11 11-12
exact bonds :
1-2 2-3

```

G1:NO2

Match level :

```

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:CLASS



```

L3 STRUCTURE UPLOADED

=> D

L3 HAS NO ANSWERS

L3 STR



G1 NO2

Structure attributes must be viewed using STN Express query preparation.

```
=> S L3
SAMPLE SEARCH INITIATED 14:17:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -          0 TO ITERATE

100.0% PROCESSED      0 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          0 TO      0
PROJECTED ANSWERS:            0 TO      0
```


L4 0 SEA SSS SAM L3

```
=> S L3 FULL
FULL SEARCH INITIATED 14:17:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -          2 TO ITERATE

100.0% PROCESSED      2 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01
```

L5 0 SEA SSS FUL L3

=> Uploading C:\Program Files\STNEXP\Queries\10581340\3.str



```
chain nodes :
1 2 3 4 5 11
ring nodes :
6 7 8 9 10
chain bonds :
1-2 2-3 2-4 3-5 10-11
ring bonds :
6-7 6-10 7-8 8-9 9-10
exact/norm bonds :
2-4 3-5 6-7 6-10 7-8 8-9 9-10 10-11
exact bonds :
1-2 2-3
```


G1:NO2

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom
 10:Atom 11:CLASS

L6 STRUCTURE UPLOADED

=> D
 L6 HAS NO ANSWERS
 L6 STR



G1 NO2

Structure attributes must be viewed using STN Express query preparation.

=> S L6
 SAMPLE SEARCH INITIATED 14:18:39 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 0 TO 0
 PROJECTED ANSWERS: 0 TO 0



L7 0 SEA SSS SAM L6

=> S L6 FULL
 FULL SEARCH INITIATED 14:18:43 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

L8 0 SEA SSS FUL L6

=>
 Uploading C:\Program Files\STNEXP\Queries\10581340\4.str




chain nodes :
 1 2 3 4 5 7 8

chain bonds :
 1-2 2-3 2-4 3-5 7-8

exact/norm bonds :
 2-4 3-5 7-8
 exact bonds :
 1-2 2-3

G1:NO2

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:CLASS



Structure attributes must be viewed using STN Express query preparation.

=> S L9
 SAMPLE SEARCH INITIATED 14:22:10 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 217 TO ITERATE

100.0% PROCESSED 217 ITERATIONS 4 ANSWERS
 SEARCH TIME: 00.00.01

10/581,340


09/19/2008

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3457 TO 5223
PROJECTED ANSWERS: 4 TO 200

L10 4 SEA SSS SAM L9

=> D SCAN


L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Propanoic acid, 2-oxo-, 2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl ester
 MF C6 H8 N2 O9



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Propanoic acid, 2-oxo-, 2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl
 ester
 MF C7 H9 N3 O11



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> S L9 FULL
FULL SEARCH INITIATED 14:22:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4141 TO ITERATE

100.0% PROCESSED 4141 ITERATIONS
SEARCH TIME: 00.00.01
```

```
L11 122 SEA SSS FUL L9
```

=> FIL CAPLUS	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	538.76	538.97

FILE 'CAPLUS' ENTERED AT 14:22:35 ON 19 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 18 Sep 2008 (20080918/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> S L11
L12 9 L11
=> D IBIB 1
```

L12 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008333268 CAPLUS
DOCUMENT NUMBER: 148:449109
TITLE: Thermal stability of carbonyl radicals. Part II.
Reactions of methylglyoxyl and methylglyoxylperoxy
radicals at 1 bar in the temperature range 275-311 K
AUTHOR(S): Jagiella, Stefan; Zabel, Friedhelm
CORPORATE SOURCE: Institut fuer Physikalische Chemie, Universitaet
Stuttgart, Stuttgart, D-70569, Germany
SOURCE: Physical Chemistry Chemical Physics (2008), 10(13),
1799-1808
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:588522 CAPLUS
 DOCUMENT NUMBER: 143:120530
 TITLE: Nitric oxide-releasing pyruvate compounds, compositions and methods for treating cardiovascular and other diseases
 INVENTOR(S): Garvey, David S.; Fang, Xinqin; Subhash, Khanapure
 P. i Ramani, Ranatunga R.; Shiow-Jyi, Wey
 PATENT ASSIGNEE(S): Nitromed, Inc., USA
 SOURCE: PCT Int. Appl., 82 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060603	A3	20050707	WO 2004-US41069	20041210
WO 2005060603	A3	20051201		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GN, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BY, CF, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004305016	A1	20050707	AU 2004-305016	20041210
CA 2549412	A1	20050707	CA 2004-2549412	20041210
EP 1632107	A2	20060823	EP 2004-813393	20041210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:			US 2003-528184P	P 20031210
			WO 2004-US41069	W 20041210

OTHER SOURCE(S): MARPAT 143:120530

L12 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:432749 CAPLUS
DOCUMENT NUMBER: 143178225
TITLE: Atmospheric Chemistry of C3-C6
Cycloalkanecarbaldehydes
AUTHOR(S): D'Anna, Barbara; Wisthaler, Armin; Andreasen,
Oeyvind;
COPORATE SOURCE: Hansel, Armin; Hjorth, Jens; Jensen, Niels R.;
Nielsen, Claus J.; Stenstrom, Yngve; Viidanoja, Jyrki
Department of Chemistry, University of Oslo, Oslo,
N-0315, Norway
SOURCE: Journal of Physical Chemistry A (2005), 109 (23),
5104-5113
PUBLISHER: CODEN: JPCAPH; ISSN: 1089-5639
American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR
THIS
FORMAT: RECORD. ALL CITATIONS AVAILABLE IN THE RE

L12 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:804127 CAPLUS
DOCUMENT NUMBER: 141:405654
TITLE: NO-Sartans: A New Class of Pharmacodynamic Hybrids as
Cardiovascular Drugs
Breschi, Maria C.; Calderone, Vincenzo; Digiocomo,
Maria; Martelli, Alma; Martinotti, Enrica; Minutolo,
Filippo; Rapposelli, Simona; Balsamo, Aldo
Dipartimento di Psichiatria, Neurobiologia,
Farmacologia e Biotecnologie, Universita di Pisa,
Pisa, 56126, Italy
Journal of Medicinal Chemistry (2004), 47(23),
5597-5600
CODEN: JMMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:405654
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L12 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:432749 CAPLUS
DOCUMENT NUMBER: 1431:178225
TITLE: Atmospheric Chemistry of C3-C6
Cycloalkanecarbaldehydes
AUTHOR(S): D'Anna, Barbara; Wisthaler, Armin; Andreasen,
Oeyvind;
COPORATE SOURCE: Hansel, Armin; Hjorth, Jens; Jensen, Niels R.;
Nielsen, Claus J.; Stenstrom, Yngve; Viidanoja, Jyrki
Department of Chemistry, University of Oslo, Oslo,
N-0315, Norway
SOURCE: Journal of Physical Chemistry A (2005), 109 (23),
5104-5113
CODEN: JPCAPH; ISSN: 1089-5639
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR
THIS
FORMAT: RECORD. ALL CITATIONS AVAILABLE IN THE RE

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 SESSION NUMBER: 2005:588522 CAPLUS
 DOCUMENT NUMBER: 143:120530
 TITLE: Nitric oxide-releasing pyruvate compounds, compositions and methods for treating cardiovascular and other diseases
 INVENTOR(S): Garvey, David S.; Fang, Xinqin; Subhash, Khanapure P.;
 PATENT ASSIGNEE(S): Ranamit, Ranatunga R.; Shiow-Jyi, Wey Nitromed, Inc., USA
 SOURCE: PCT Int. Appl. '82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060603	A2	20050707	WO 2004-US41069	20041210
WO 2005060603	A3	20051201		
W: AU, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GN, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BY, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2004305016	A1	20050707	AU 2004-305016	20041210
CA 2549412	A1	20050707	CA 2004-2549412	20041210
EP 1632107	A2	20060823	EP 2004-813393	20041210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:		US 2003-528184P	P	20031210
		WO 2004-US41069	W	20041210

OTHER SOURCE(S): MARPAT 143:120530
 AB The invention describes novel pyruvate compds. comprising at least one nitric oxide-releasing group and pharmaceutically acceptable salts thereof, and compns. and kits comprising at least one of these pyruvate compds., and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The therapeutic agent is, e.g., an aldosterone antagonist, α -adrenoceptor antagonist, an angiotensin II antagonist, an ACE inhibitor, an antidiabetic, an antihyperlipidemic agent, an antioxidant, an antithrombotic, a vasodilator, a β -adrenoceptor antagonist, a calcium channel blocker, a digitalis, a diuretic, etc. The invention also provides methods for treating cardiovascular diseases, renovascular diseases, diabetes, diseases resulting from oxidative stress, endothelial dysfunctions, diseases caused by endothelial dysfunctions,


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 857465-26-0P 857465-27-1P 857465-28-2P
 857465-29-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of nitric oxide-releasing pyruvate compds. and compns. for treating cardiovascular and other diseases)
 RN 857464-11-0 CAPLUS
 CN 1,2-Propanedione, 1-[4-(nitrooxy)-1-piperidinyl]- (CA INDEX NAME)



RN 857464-12-1 CAPLUS
 CN Propanamide, N-[3-(nitrooxy)propyl]-2-oxo- (CA INDEX NAME)



RN 857464-13-2 CAPLUS
 CN Propanamide, N-[2,2-dimethyl-3-(nitrooxy)propyl]-2-oxo- (CA INDEX NAME)



RN 857464-14-3 CAPLUS
 CN Propanamide, N-[1S)-2-(nitrooxy)-1-phenylethyl]-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-15-4 CAPLUS
 CN Propanamide, N-[1S)-1-[(nitrooxy)methyl]-2-phenylethyl]-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 cirrhosis, pre-eclampsia, osteoporosis, nephropathy, reperfusing injury following ischemia, and/or preserving tissues, organs, organ parts and/or limbs using these compns. The nitric oxide releasing group is preferably a nitro group, a nitroso group, and/or a heterocyclic nitric oxide donor group. The heterocyclic nitric oxide donor group is preferably a furoxan,


a sydnonimine, an oxatriazole-5-one and/or an oxatriazole-5-imine. Thus, a mixt. of nitrooxy-4-piperidinyl nitrate (1.045 g, 5 mmol) and pyruvic acid (440 mg, 5 mmol) in dichloromethane was treated with triethylamine (0.7 mL). To this soln. was added 1-ethyl-3-(3-dimethylaminopropyl)carbamide hydrochloride (EDAC) (960 mg, 5 mmol) followed by dimethylaminopyridine (DMAP, 610 mg, 5 mmol). The resulting soin, was then stirred under nitrogen atm. at room temp. overnight. The reaction mixt. was dild. with dichloromethane and washed with water, brine, dried over sodium sulfate, filtered, and the solvent was evapd. at reduced pressure. The product was purified by column chromatog. to give 1-[4-(nitrooxy)piperidyl]propane-1,2-dione (470 mg, 44% yield) as a colorless thick oil.

IT 857464-11-0P 857464-12-1P 857464-13-2P
 857464-14-3P 857464-15-4P 857464-18-7P
 857464-19-8P 857464-20-1P 857464-21-2P
 857464-22-3P 857464-23-4P 857464-24-5P
 857464-25-6P 857464-26-7P 857464-27-8P
 857464-29-9P 857464-30-3P 857464-31-4P
 857464-32-5P 857464-33-6P 857464-34-7P
 857464-36-1P 857464-39-4P 857464-40-5P
 857464-41-6P 857464-42-7P 857464-43-8P
 857464-44-9P 857464-45-0P 857464-46-1P
 857464-47-2P 857464-48-3P 857464-49-4P
 857464-50-7P 857464-51-8P 857464-52-9P
 857464-53-0P 857464-54-1P 857464-55-2P
 857464-56-3P 857464-57-4P 857464-58-5P
 857464-59-6P 857464-60-9P 857464-61-0P
 857464-62-1P 857464-63-2P 857464-64-3P
 857464-65-4P 857464-66-5P 857464-67-6P
 857464-68-7P 857464-69-8P 857464-70-1P
 857464-71-2P 857464-72-3P 857464-73-4P
 857464-77-8P 857464-78-9P 857464-79-0P
 857464-80-3P 857464-81-4P 857464-82-5P
 857464-83-6P 857464-84-7P 857464-85-8P
 857464-86-9P 857464-87-0P 857464-88-1P
 857464-89-2P 857464-90-5P 857464-91-6P
 857464-92-7P 857464-93-8P 857464-94-9P
 857464-95-0P 857464-96-1P 857464-97-2P
 857464-98-3P 857464-99-4P 857465-00-0P
 857465-01-1P 857465-02-2P 857465-03-3P
 857465-04-4P 857465-05-5P 857465-06-6P
 857465-07-7P 857465-08-8P 857465-09-9P
 857465-10-2P 857465-11-3P 857465-12-4P
 857465-13-5P 857465-14-6P 857465-15-7P
 857465-16-8P 857465-21-5P 857465-22-6P
 857465-23-7P 857465-24-8P 857465-25-9P


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-18-7 CAPLUS
 CN Propionic acid, 2-oxo-, [3-(nitrooxy)methyl]phenylmethyl ester (CA INDEX NAME)



RN 857464-19-8 CAPLUS
 CN Propionic acid, 2-oxo-, [4-(nitrooxy)-1-piperidinyl]methyl ester (CA INDEX NAME)




RN 857464-20-1 CAPLUS
 CN Propionic acid, 2-oxo-, 2-[4-(nitrooxy)-1-piperidinyl]ethyl ester (CA INDEX NAME)



RN 857464-21-2 CAPLUS
 CN Propionic acid, 2-oxo-, 3-[4-(nitrooxy)-1-piperidinyl]propyl ester (CA INDEX NAME)


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)




RN 857464-22-3 CAPLUS
 CN Propanoic acid, 2-oxo-, (2R)-2,3-bis(nitrooxy)propyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-23-4 CAPLUS
 CN Propanoic acid, 2-oxo-, [4-[2-(nitrooxy)ethyl]phenyl]methyl ester (CA INDEX NAME)




RN 857464-24-5 CAPLUS
 CN Propanoic acid, 2-oxo-, [4-[(nitrooxy)methyl]-1-piperazinyl]methyl ester (CA INDEX NAME)




RN 857464-25-6 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-[4-[(nitrooxy)methyl]-1-piperazinyl]ethyl ester (CA INDEX NAME)


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 857464-30-3 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-[4-[2-(nitrooxy)ethyl]-1-piperazinyl]propyl ester (CA INDEX NAME)




RN 857464-31-4 CAPLUS
 CN Propanoic acid, 2-oxo-, [4-[3-(nitrooxy)propyl]-1-piperazinyl]methyl ester (CA INDEX NAME)



RN 857464-32-5 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-[4-[3-(nitrooxy)propyl]-1-piperazinyl]ethyl ester (CA INDEX NAME)




RN 857464-33-6 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-[4-[3-(nitrooxy)propyl]-1-piperazinyl]propyl ester (CA INDEX NAME)




RN 857464-34-7 CAPLUS
 CN 1,2-Propanedione, 1-[2-[(nitrooxy)methyl]-1-piperidinyl]- (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)




RN 857464-26-7 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-[4-[(nitrooxy)methyl]-1-piperazinyl]propyl ester (CA INDEX NAME)



RN 857464-27-8 CAPLUS
 CN Propanoic acid, 2-oxo-, [4-[2-(nitrooxy)ethyl]-1-piperazinyl]methyl ester (CA INDEX NAME)




RN 857464-29-0 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-[4-[2-(nitrooxy)ethyl]-1-piperazinyl]ethyl ester (CA INDEX NAME)




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 857464-30-3 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-[4-[2-(nitrooxy)ethyl]-1-piperazinyl]propyl ester (CA INDEX NAME)


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 857464-35-8 CAPLUS
 CN 1,2-Propanedione, 1-[3-[(nitrooxy)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 857464-36-9 CAPLUS
 CN 1,2-Propanedione, 1-[4-[(nitrooxy)methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 857464-37-0 CAPLUS
 CN L-Cysteine, S-[3-[(2-[(nitrooxy)ethoxy]ethyl)amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-38-1 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[[2-[(nitrooxy)ethoxy]ethyl]amino]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-39-2 CAPLUS
 CN L-Cysteine, S-[3-[2-[4-[2-(nitrooxy)ethoxy]phenoxy]ethoxy]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-40-5 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[2-[4-[2-(nitrooxy)ethoxy]phenoxy]ethoxy]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 857464-45-0 CAPLUS
 CN L-Cysteine, S-[3-[(3-(nitrooxy)propyl)amino]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 857464-46-1 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-(nitrooxy)propyl ester (CA INDEX NAME)



RN 857464-47-2 CAPLUS
 CN Propanoic acid, 2-oxo-, 2,2-dimethyl-3-(nitrooxy)propyl ester (CA INDEX NAME)



RN 857464-48-3 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester (CA INDEX NAME)




RN 857464-49-4 CAPLUS

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 857464-41-6 CAPLUS
 CN L-Cysteine, S-[3-[(3-[(nitrooxy)methyl]phenyl)methoxy]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-42-7 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[(3-[(nitrooxy)methyl]phenyl)methoxy]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-43-8 CAPLUS
 CN D-Cysteine, S-[3-[(4-[(nitrooxy)methyl]phenyl)methoxy]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-44-9 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[(4-[(nitrooxy)methyl]phenyl)methoxy]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN Propanoic acid, 2-oxo-, 2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl ester (CA INDEX NAME)


RN 857464-50-7 CAPLUS
 CN Propanamide, N-[1,3-bis(nitrooxy)propyl]-2-oxo- (CA INDEX NAME)



RN 857464-51-8 CAPLUS
 CN Propanoic acid, 2-oxo-, [3,5-bis(nitrooxy)methyl]phenylmethyl ester (CA INDEX NAME)




RN 857464-52-9 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-methyl-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester (CA INDEX NAME)




RN 857464-53-0 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propyl ester (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)




RN 857464-54-1 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-[4-[(nitrooxy)ethoxy]phenoxy]ethyl ester (CA INDEX NAME)



RN 857464-55-2 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester (CA INDEX NAME)




RN 857464-56-3 CAPLUS
 CN Propanamide, N-[2-[(nitrooxy)ethoxy]ethyl]-2-oxo- (CA INDEX NAME)



RN 857464-57-4 CAPLUS
 CN Propanoic acid, 2-oxo-, [4-[(nitrooxy)methyl]phenyl]methyl ester (CA INDEX NAME)


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)




RN 857464-58-5 CAPLUS
 CN L-Glutamic acid, 5-[2-[(1,2-dioxopropyl)amino]-3-(nitrooxy)-2-(nitrooxy)methyl]propyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-59-6 CAPLUS
 CN L-Glutamine, N-[2-(1,2-dioxopropoxy)-1,1-bis[(nitrooxy)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-60-9 CAPLUS
 CN L-Glutamic acid, 5-[2-[(1,2-dioxopropoxy)methyl]-3-(nitrooxy)propyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-61-0 CAPLUS
 CN L-Glutamic acid, 5-[2-[(1,2-dioxopropoxy)methyl]-2-methyl-3-(nitrooxy)propyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-62-1 CAPLUS
 CN L-Glutamic acid, 5-[2-(1,2-dioxopropoxy)-1,1-bis[(nitrooxy)methyl]ethyl] ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-63-2 CAPLUS
 CN L-Glutamic acid, 5-[1-[(1,2-dioxopropoxy)methyl]-1-nitro-2-(nitrooxy)ethyl] ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-64-3 CAPLUS
 CN L-Glutamic acid, 5-[1-[(1,2-dioxopropoxy)methyl]-2-(nitrooxy)ethyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-65-4 CAPLUS
 CN L-Glutamic acid, 5-[(3-[(1,2-dioxopropoxy)methyl]-5-[(nitrooxy)methyl]phenyl)methyl] ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-66-5 CAPLUS
 CN L-Glutamic acid, 5-[2-(1,2-dioxopropoxy)-3-(nitrooxy)propyl] ester (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)




RN 857464-67-6 CAPLUS
 CN L-Glutamic acid, 5-[1-(1,2-dioxopropoxy)methyl]-2-(nitrooxy)ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-68-7 CAPLUS
 CN L-Glutamine, N-[1-(1,2-dioxopropoxy)methyl]-2-(nitrooxy)ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-69-8 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[3-(nitrooxy)propyl]amino]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-73-4 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[2-(nitrooxy)-1-(nitrooxy)methyl]amino]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-74-5 CAPLUS
 CN L-Cysteine, S-[3-(3-(nitrooxy)-2,2-bis(nitrooxy)methyl)propoxy]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-75-6 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-(3-(nitrooxy)-2,2-bis(nitrooxy)methyl)propoxy]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)




RN 857464-70-1 CAPLUS
 CN L-Cysteine, S-[3-[2,2-dimethyl-3-(nitrooxy)propyl]amino]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-71-2 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[2,2-dimethyl-3-(nitrooxy)propyl]amino]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-72-3 CAPLUS
 CN L-Cysteine, S-[3-[2-(nitrooxy)-1-(nitrooxy)methyl]amino]-2,3-dioxopropyl-, 2-methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-76-8 CAPLUS
 CN L-Cysteine, S-[3-[2-methyl-3-(nitrooxy)-2-(nitrooxy)methyl]propoxy]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-77-8 CAPLUS
 CN L- γ -glutamyl-S-[3-[2-methyl-3-(nitrooxy)-2-(nitrooxy)methyl]propoxy]-2,3-dioxopropyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-78-9 CAPLUS
 CN L-Cysteine, S-[3-[2-nitro-3-(nitrooxy)-2-(nitrooxy)methyl]propoxy]-2,3-dioxopropyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 857464-79-0 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-80-3 CAPLUS
 CN L-Cysteine, S-[3-[3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-81-4 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-82-5 CAPLUS
 CN L-Cysteine, S-[3-[2,2-dimethyl-3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 857464-86-9 CAPLUS
 CN L-Cysteine, S-[3-[2-(nitrooxy)-1-[(nitrooxy)methyl]ethoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-87-0 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[2-(nitrooxy)-1-[(nitrooxy)methyl]ethoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-88-1 CAPLUS
 CN L-Cysteine, S-[3-[3,5-bis[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-89-2 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[3,5-bis[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-83-6 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[2,2-dimethyl-3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-84-7 CAPLUS
 CN L-Cysteine, S-[3-[3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-85-8 CAPLUS
 CN L-Cysteine, L- γ -glutamyl-S-[3-[3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 857464-90-5 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2-(nitrooxy)ethoxy]ethyl]amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-90-5 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2-(nitrooxy)ethoxy]ethyl]amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-91-6 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[3-(nitrooxy)propyl]amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-92-7 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2-(4-(2-(nitrooxy)ethoxy)phenoxy]ethoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-93-8 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2,2-dimethyl-3-(nitrooxy)propyl]amino]-2,3-

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
dioxopropyl], methyl ester (CA INDEX NAME)


(Continued)

Absolute stereochemistry.




RN 857464-94-9 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[3-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-95-0 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl]amino]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-96-1 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[4-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)




RN 857464-97-2 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[(nitrooxy)-2,2-bis[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-98-3 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[(2-methyl-3-(nitrooxy)-2-(nitrooxy)methyl)propoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-99-4 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[(2-nitro-3-(nitrooxy)-2-(nitrooxy)methyl)propoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-00-0 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[2-(nitrooxy)-1-[(nitrooxy)methyl]ethoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-01-1 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[3-(nitrooxy)propoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-02-2 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[3,5-bis[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-03-3 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[(2,2-dimethyl-3-(nitrooxy)propoxy)-2,3-dioxopropyl, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-04-4 CAPLUS
CN L-Glutamic acid, 5-[(2S)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl] ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-05-5 CAPLUS
CN L-Glutamic acid, 5-[(2S)-3-[(2S)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl] ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-06-6 CAPLUS
 CN L-Ornithine, N2-(1,2-dioxopropyl)-N5-L-γ-glutamyl-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-07-7 CAPLUS
 CN L-Ornithine, N2-(1,2-dioxopropyl)-N5-L-γ-glutamyl-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-08-8 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-12-4 CAPLUS
 CN L-Lysinamide, N-[(2R)-2,3-bis(nitrooxy)propyl]-N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-13-5 CAPLUS
 CN L-Lysinamide, N-[(2S)-2,3-bis(nitrooxy)propyl]-N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-14-6 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-[(3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-09-9 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-10-2 CAPLUS
 CN L-Norvaline, 5-[(2R)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl]thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-11-3 CAPLUS
 CN L-Norvaline, 5-[(2S)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl]thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-15-7 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-ester with 3,6-anhydro-2-deoxy-β-L-glycero-hexofuranose 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-16-8 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-ester with 3,6-anhydro-2-deoxy-β-D-glycero-hexofuranose 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-21-5 CAPLUS
 CN L-Lysine, L-γ-glutamyl-N6-(1,2-dioxopropyl)-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)




RN 857465-22-6 CAPLUS
 CN L-Lysine, L-γ-glutamyl-N6-(1,2-dioxopropyl)-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-23-7 CAPLUS
 CN L-Lysinamide, L-γ-glutamyl-N-[(2R)-2,3-bis(nitrooxy)propyl]-N6-(1,2-dioxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-24-8 CAPLUS
 CN L-Lysinamide, L-γ-glutamyl-N-[(2S)-2,3-bis(nitrooxy)propyl]-N6-(1,2-dioxopropyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)

Absolute stereochemistry.




RN 857465-25-9 CAPLUS
 CN L-Serine, L-γ-glutamyl-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester, 2-oxopropanoate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-26-0 CAPLUS
 CN L-Serine, L-γ-glutamyl-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester, 2-oxopropanoate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 857465-27-1 CAPLUS


CN L-Ornithine, L-γ-glutamyl-N5-(1,2-dioxopropyl)-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-28-2 CAPLUS
 CN L-Ornithine, L-γ-glutamyl-N5-(1,2-dioxopropyl)-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-29-3 CAPLUS
 CN L-Cysteine, N-acetyl-L-S-[3-[3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:585947 CAPLUS

DOCUMENT NUMBER: 135:361671

TITLE: New methodology for ozone depletion potentials of short-lived compounds: N-propyl bromide as an example

AUTHOR(S): Wuebbles, Donald J.; Patten, Kenneth O.; Johnson, Matthew T.; Kotamarthi, Rao

CORPORATE SOURCE: Department of Atmospheric Sciences, University of Illinois, Urbana, IL USA

SOURCE: Journal of Geophysical Research, [Atmospheres]

(2001), 106(D13), 14551-14571

PUBLISHER: CODEN: JGDE3; ISSN: 0148-0227

American Geophysical Union

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A number of the compds. proposed as replacements for substances controlled under the Montreal Protocol have extremely short atmospheric lifetimes, on the

order of days to a few months. An important example is Pr bromide (also referred to as 1-bromopropane, CH₂BrCH₂CH₃ or simplified as 1-C₃H₇Br or nPB). This compound, useful as a solvent, has an atmospheric lifetime of <20 days due to its reaction with hydroxyl radicals. Because nPB contains bromine, any amount reaching the stratosphere has the potential to affect concns.

of stratospheric ozone. The definition of ozone depletion potentials (ODPs) needs to be modified for such short-lived compds. to account for the location and timing of emissions. It is not adequate to treat these chems. as if they were uniformly emitted at all latitudes and longitudes as is normally done for longer-lived gases. Thus, for short-lived compds., policymakers will need a table of ODP values instead of the single value generally provided in past studies. This study uses the MOZART2 3-dimensional chemical transport model in combination with studies with our less computationally expensive 2-dimensional model to examine the

potential effects of nPB on stratospheric ozone. Multiple facets of this study examine key questions regarding the amount of bromine reaching the stratosphere following emission of nPB. Our most significant findings from this study for the purposes of short-lived replacement compound ozone

effects are summarized as follows. The degradation of nPB produces a significant quantity of bromoacetone, which increases the amount of bromine transported to the stratosphere due to nPB. However, much of that effect is not due to bromoacetone itself, but instead to inorg. bromine which is produced from tropospheric oxidation of nPB, bromoacetone, and other degradation

products and is transported above the dry and wet deposition processes of the model. The MOZART2 nPB results indicate a minimal correction of the 2-dimensional results in order to derive our final results: an nPB chemical

lifetime of 19 days and an ODP range of 0.033 to 0.040 for assumed global emissions over landmasses, 19 days and 0.021 to 0.028, resp., for assumed emissions in the industrialized regions of the Northern Hemisphere, and 9 days and 0.087 to 0.105, resp., for assumed emission in tropical

South

L12 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Asia.

IT

RL: GPF (Geological or astronomical process); POL (Pollutant); RCT (Reactant); OCCU (Occurrence); PROC (Process); RACT (Reactant or reagent) (formation from PrBr and calcn. of atmospheric half-life and rainout lifetime; new methodol. for calcn. of ozone depletion potentials of short-lived compds. such as Pr bromide)

RN 340171-63-3 CAPLUS

CN 2-Propanone, 3-bromo-1-(nitrodioxy)-1-oxo- (CA INDEX NAME)



RN 372952-10-8 CAPLUS

CN Propanoyl bromide, 3-(nitrodioxy)-2,3-dioxo- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 2001:287681 CAPLUS
DOCUMENT NUMBER: 134:370967

TITLE: Effects of n-propyl bromide and other short lived chemicals on stratospheric ozone

AUTHOR(S): Wuebbles, Donald J.; Patten, Kenneth O.; Johnson, Matthew T.

CORPORATE SOURCE: University of Illinois, Urbana, IL, 61801, USA
SOURCE: Symposium on Atmospheric Chemistry Issues in the 21st Century, [Preprints], Long Beach, CA, United States, Jan. 9-14, 2000 (2000), 77-84. American Meteorological Society: Boston, Mass.

CODEN: 69BES4
DOCUMENT TYPE: Conference
LANGUAGE: English

AB This study uses the MCCART three-dimensional model in combination with studies with a less computationally expensive two-dimensional model to examine potential effects of Pr bromide (nPB) on stratospheric ozone. Multiple facets of this study examine key questions regarding the amount of bromine reaching the stratosphere following emission of nPB.

IT 340171-63-3
RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); POL (Pollutant); FORM (Formation, nonpreparative); OCCU (Occurrence); PROC (Process) (effects of Pr bromide and other short lived chems. on stratospheric ozone)

RN 340171-63-3 CAPLUS
CN 2-Propanone, 3-bromo-1-(nitrodioxy)-1-oxo- (CA INDEX NAME)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
ACCESSION NUMBER: 1992:1531499 CAPLUS
DOCUMENT NUMBER: 117:131499
ORIGINAL REFERENCE NO.: 117:22851a,22854a
TITLE: Preparation of hexitol derivatives as cardiovascular agents.


INVENTOR(S): Suzuki, Fumio; Hayashi, Hiroaki; Kubo, Kazuhiro; Ikeda, Junichi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo K. K., Japan
SOURCE: Eur. Pat. Appl., 22 pp.DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 485723	A1	19920520	EP 1991-116540	19910927
EP 485723	B1	19940914		
DE, FR, GB, IT				
US 5120737	A	19920609	US 1991-764827	19910924
CA 2052082	A1	19920329	CA 1991-2052082	19910926
CA 2052082	C	19970527		
JP 04364184	A	19921216	JP 1991-247958	19910926
JP 3058955	B2	20000704		
PRIORITY APPLN. INFO.:			JP 1990-259385	A 19900928

OTHER SOURCE(S): MARPAT 117:131499
GI

AB Title compds. I [R = H, (un)substituted alkylcycloalkyl, alkenyl, alkoxy, alkanoyl, piperidyn, X(CH₂)_mCYZ(CH₂)_n] wherein m, n = 0-3, X, Y, Z = H, alkyl, alkoxy, alkanoyl, alkanoyloxy, HO, halo, O2N] or a salt thereof, useful as vasodilators, are prepared 5-Deoxy-5-(piperazin-1-yl)-1,4:3,6-dianhydro-L-iditol-2-nitrate (preparation given) in CH₂Cl₂ was stirred at 0° and reacted with Ac₂O and pyridine to give after workup L-1 (R = Me) which was converted to the HCl salt (II). In a test for coronary vasospasm model in rats, II showed a min. effectiveness of <30 mg/kg,

p.o. Pharmaceutical formulations comprising I are given.

IT 143253-72-9P 143277-70-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as vasodilator)


RN 143253-72-9 CAPLUS

CN L-Iditol,

1,4:3,6-dianhydro-2-deoxy-2-[4-(1,2-dioxopropyl)-1-piperazinyl]-5-nitrate (9CI) (CA INDEX NAME)

L12 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
, 5-nitrate, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143277-70-7 CAPLUS

CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[4-(1,2-dioxopropyl)-1-piperazinyl]-5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:121161 CAPLUS

DOCUMENT NUMBER: 84:121161

ORIGINAL REFERENCE NO.: 84:19665a,19668a

TITLE: 1,4-Disubstituted 2,3-butanediones

INVENTOR(S): Nikolaeva, A. D.; Kirsanov, A. P.

PATENT ASSIGNEE(S): Kazan Chemical-Technological Institute, USSR

SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1976, 53(8), 52.

CODEN: URXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 504749	A1	19760228	SU 1974-2017453	19740419
PRIORITY APPN. INFO.:			SU 1974-2017453	A 19740419


AB RCH₂COOCOCH₂R (R = halo, alkoxy, ONO₂) were prepared by N₂O₄ oxidation of RCH₂C=OCH₂R in a refluxing halogenated hydrocarbon.

IT 58246-23-4P

KL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 58246-23-4 CAPLUS

CN 2,3-Butanedione, 1,4-bis(nitrooxy)- (CA INDEX NAME)



L12 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:73584 CAPLUS

DOCUMENT NUMBER: 84:73584

ORIGINAL REFERENCE NO.: 84:12063a,12066a

TITLE: Synthesis of nitrates of some acetylene and diacetylene alcohols

AUTHOR(S): Nikolaeva, A. D.; Kirsanov, A. P.; Kadyrova, R. G.

CORPORATE SOURCE: Kazan, Khim.-Tekhnol. Inst. im. Kirova, Kazan, USSR

SOURCE: Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya (1975), 18(11), 1715-16

CODEN: JVUKAR; ISSN: 0579-2991

JOURNAL: Journal

LANGUAGE: Russian

AB Treating RC.tplbond.CCH₂OX (I; R = H, Me, NOCH₂, NOCH₂C.tplbond.C; X = H) and RIC.tplbond.CCHMeOX (II; R₁ = H, NOCHMeC.tplbond.C; X = H) with HNO₃ in CH₂Cl₂ or Ac₂O, or with N₂O₄ in CCl₄ afforded the resp. I (X = NO₂)

and

II (X = NO₂) in \leq 71.5% yield.

IT 58246-23-4P

KL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and borohydride reduction of)

RN 58246-23-4 CAPLUS

CN 2,3-Butanedione, 1,4-bis(nitrooxy)- (CA INDEX NAME)

